Newsroom

LONDON--(BUSINESS WIRE)--  08 December 2025 YOUNG & CO.’S BREWERY, P.L.C. Transaction in own shares Young & Co.’s Brewery, P.L.C. (the “Company”) announces that on 05 December 2025, in accordance with the terms of its share buyback programme announced by the Company on 17 November 2025 (the “Share Buyback Programme”), it has purchased the following Non-voting ordinary shares of 12.5 pence each (“Non-voting Shares” and the “Purchased Shares”) in the Company through Peel Hunt LLP (“Peel H...

BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 5 December 2025 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 5 December 2025 Number of Public Shares Purchased: 29...

CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)--Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, announces the intensification of its collaboration with Entreprise de Construction et Bâtiment du Littoral (E.C.B.L.), a general construction company based in Rochefort (17). Three...

CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)--Regulatory News: Hoffmann Green Cement Technologies (ISIN : FR0013451044, Mnémo : ALHGR) (« Hoffmann Green Cement » ou la « Société »), acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, annonce l’intensification de sa collaboration avec l’Entreprise de Construction et Bâtiment du Littoral (E.C.B.L.), entreprise générale du bâtiment implantée à Rochefort...

LONDON--(BUSINESS WIRE)--  First Trust Global Portfolios Management Limited (“FTGPM”) announces the declaration of the quarterly distributions for the following sub-funds of First Trust Global Funds plc, ISIN Fund Name Frequency Dividend per Share IE00BZBW4Z27 First Trust US Equity Income UCITS ETF Class A Quarterly $0.2285 (USD) IE00BWTNMB87 First Trust US Large Cap Core AlphaDEX® UCITS ETF Class B Quarterly $0.1305 (USD) IE00BD9N0445 First Trust United Kingdom AlphaDEX® UCITS ETF Class B Quar...

FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our r...

ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--BigBear.ai, a leading provider of mission-ready AI for defense, intelligence and commercial customers, today announced the opening of its first Middle East office at the World Trade Center Abu Dhabi as part of its significant, long-term investment in the region. Kevin McAleenan, President & CEO of BigBear.ai and former Acting U.S. Secretary of the Department of Homeland Security (DHS), made the announcement at the Global AI Show. He went on...

東京--(BUSINESS WIRE)--（ビジネスワイヤ） -- 株式会社スクウェア・エニックス・ホールディングス（以下「スクエニHD」）（9684.T）の大株主であるファンドに対して、投資一任業務を提供する3D Investment Partners Pte. Ltd.（「3D」又は「当社」）は、本日、スクエニHDが長年抱えている経営課題を説明したプレゼンテーション資料（以下「本プレゼン資料」）を公開しました。当社は、株主の皆様のご意見を踏まえて、スクエニHDと企業価値向上に向けた建設的な対話を進めて参りたいと考えておりますので、株主の皆様におかれましては、本プレゼン資料をご覧くださいまして、スクエニHDの経営課題について率直なご意見をくださいますようお願い申し上げます。 Link: https://www.3dipartners.com/wp-content/uploads/square-enix-presentation-material-jp-202512.pdf （本プレゼン資料のp.93までのスライドは、2025年9月29日に当社がスクエニHDに提供した経営課題指摘資料...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Data Monitoring Committee (DMC) supports the continuation of the Audiogene Phase 1/2 clinical trial of SENS-501, the Company’s gene therapy program being developed to treat a specific form of congenital deafness linked to mutations...